Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study

被引：0
|
作者：
Makoto Sakai
Makoto Sohda
Hideyuki Saito
Kengo Kuriyama
Tomonori Yoshida
Yuji Kumakura
Keigo Hara
Takehiko Yokobori
Tatsuya Miyazaki
Kazutoshi Murata
Shin-ei Noda
Takashi Nakano
Hiroyuki Kuwano
Ken Shirabe
机构：
[1] Gunma University,Department of General Surgical Science, Graduate School of Medicine
[2] Gunma University Graduate School of Medicine,Department of Innovative Cancer Immunotherapy
[3] Gunma University Graduate School of Medicine,Department of Radiation Oncology
[4] International Medical Center,Department of Radiation Oncology
[5] Saitama Medical University,undefined
[6] Fukuoka City Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词：
Cervical esophageal cancer; Chemoradiotherapy; DCF; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1121 / 1126
页数：5
相关论文
共 50 条
  • [31] Efficacy and safety of docetaxel/cisplatin/5-fluorouracil preoperative combination chemotherapy in esophageal cancer patients with extended lymph node metastases
    Tsuyoshi Tanaka
    Yoshihiro Kinoshita
    Harushi Udagawa
    Masaki Ueno
    Kazuhisa Ehara
    Shusuke Haruta
    Sachiko Kaida
    Masatoshi Nakagawa
    Esophagus, 2012, 9 : 99 - 104
  • [32] Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma
    Satomura, Hitoshi
    Nakajima, Masanobu
    Sasaki, Kinro
    Yamaguchi, Satoru
    Domeki, Yasushi
    Takahashi, Masakazu
    Muroi, Hiroto
    Kubo, Tsukasa
    Kikuchi, Maiko
    Otomo, Haruka
    Ihara, Keisuke
    Kato, Hiroyuki
    INTERNATIONAL SURGERY, 2015, 100 (06) : 1153 - 1158
  • [33] Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients
    Yoshimoto, Takanori
    Oshima, Tadayuki
    Fukada, Takashi
    Imamura, Nobuko
    Nakanishi, Takashi
    Ebisutani, Nobuhiko
    Morishita, Daisuke
    Mieno, Masatoshi
    Nakai, Keisuke
    Sei, Hiroo
    Kitayama, Yoshitaka
    Eda, Hirotsugu
    Okugawa, Takuya
    Tomita, Toshihiko
    Fukui, Hirokazu
    Shinzaki, Shinichiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 142 - 148
  • [34] Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients
    Takanori Yoshimoto
    Tadayuki Oshima
    Takashi Fukada
    Nobuko Imamura
    Takashi Nakanishi
    Nobuhiko Ebisutani
    Daisuke Morishita
    Masatoshi Mieno
    Keisuke Nakai
    Hiroo Sei
    Yoshitaka Kitayama
    Hirotsugu Eda
    Takuya Okugawa
    Toshihiko Tomita
    Hirokazu Fukui
    Shinichiro Shinzaki
    International Journal of Clinical Oncology, 2024, 29 : 142 - 148
  • [35] Phase II study of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with node-positive esophageal cancer
    Watanabe, M.
    Nagai, Y.
    Iwagami, S.
    Miyamoto, Y.
    Hayashi, N.
    Baba, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer
    Nomura, Hisanaga
    Tsuji, Daiki
    Ueno, Shohei
    Kojima, Takashi
    Fujii, Satoshi
    Yano, Tomonori
    Daiko, Hiroyuki
    Demachi, Ken
    Itoh, Kunihiko
    Kawasaki, Toshikatsu
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 420 - 429
  • [37] Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer
    Hisanaga Nomura
    Daiki Tsuji
    Shohei Ueno
    Takashi Kojima
    Satoshi Fujii
    Tomonori Yano
    Hiroyuki Daiko
    Ken Demachi
    Kunihiko Itoh
    Toshikatsu Kawasaki
    Investigational New Drugs, 2022, 40 : 420 - 429
  • [38] COMPARATIVE COST ANALYSIS FOR DOCETAXEL, CISPLATIN AND 5-FLUOROURACIL (TPF) AND CISPLATIN AND 5-FLUOROURACIL (PF) FOR HEAD AND NECK CANCER PATIENTS
    Pantarotto, M.
    Castro, A. F.
    Estevinho, F.
    Azevedo, I.
    Dinis, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 327 - 328
  • [39] Phase II Study of Docetaxel, Cisplatin and 5-Fluorouracil (DCF) for Metastatic Esophageal Cancer (OGSG 0403)
    Tamura, Shigeyuki
    Imano, Motohiro
    Takiuchi, Hiroya
    Kobayashi, Kenji
    Imamoto, Haruhiko
    Miki, Hirofumi
    Goto, Yoshihiro
    Aoki, Taro
    Peng, Ying-Feng
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    ANTICANCER RESEARCH, 2012, 32 (04) : 1403 - 1408
  • [40] Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study
    Detailleur, Stephanie
    Segelov, Eva
    Del Re, Marzia
    Prenen, Hans
    ANNALS OF GASTROENTEROLOGY, 2021, 34 (01): : 68 - 72
12345